Lenalidomide for second-line treatment of advanced hepatocellular cancer: A brown university oncology group phase II study

Howard Safran, Kevin P. Charpentier, Andreas Kaubisch, Kalyan Mantripragada, Gregory Dubel, Kimberly Perez, Katherine Faricy-Anderson, Thomas Miner, Yoko Eng, Joel Victor, Angela Plette, Joseph Espat, Pamela Bakalarski, Patti Wingate, David Berz, Denise Luppe, Diane Martel, Kayla Rosati, Santiago Aparo

Research output: Contribution to journalArticle

11 Scopus citations

Abstract

Purpose: To assess the activity and toxicity of lenalidomide for patients with advanced hepatocellular cancer (HCC) previously treated with sorafenib. MATERIALS AND Methods: Patients with advanced HCC who progressed on or were intolerant to sorafenib were eligible. Patients received lenalidomide 25 mg orally for 1 to 21 days in a 28-day cycle until disease progression or unacceptable toxicities. Results: Forty patients were enrolled and were classified according to the Child-Pugh score: 19 were Child-Pugh A, 16 patients were Child-Pugh B, and 5 were Child-Pugh C. Seventeen patients had extrahepatic disease. Grade 4 neutropenia occurred in 1 of 40 patients (2.5%). Grade 3 fatigue (n=3) and rash (n=4) were the most common nonhematologic toxicities attributable to lenalidomide. Six of 40 patients (15%) had a partial response. Two patients (5%) have not progressed at 36 and 32 months. The median progression-free survival was 3.6 months and the median overall survival was 7.6 months. Conclusions: Lenalidomide can be administered to patients with advanced HCC and hepatic dysfunction. Promising, and in a small percentage of patients, durable activity has been demonstrated. Investigations are needed to explore the mechanism of action of lenalidomide in HCC.

Original languageEnglish (US)
Pages (from-to)1-4
Number of pages4
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume38
Issue number1
DOIs
Publication statusPublished - Feb 2 2015

    Fingerprint

Keywords

  • hepatocellular cancer
  • Lenalidomide
  • sorafenib

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this